These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 20958109)

  • 21. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
    Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L
    Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).
    Nicholls SJ; Brandrup-Wognsen G; Palmer M; Barter PJ
    Am J Cardiol; 2010 Jan; 105(1):69-76. PubMed ID: 20102893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching statins: cost of simvastatin is overestimated.
    Ashcroft JS
    BMJ; 2006 Jun; 332(7556):1512. PubMed ID: 16793831
    [No Abstract]   [Full Text] [Related]  

  • 24. LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice.
    Rublee DA; Burke JP
    Postgrad Med; 2010 Mar; 122(2):16-24. PubMed ID: 20203452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Say no to the extremes in the debate on lipid reduction].
    Hjemdahl P; Allhammar A; Eklund J; Forslund T; Hulting J; Kahan T; Martinsson A; Malmström R; Rücker F; Schenck-Gustafsson K; Schwieler J; Törnerud M; Wettermark B
    Lakartidningen; 2011 Sep 7-13; 108(36):1664-5. PubMed ID: 22032007
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug use review matters.
    Mueting M
    Nebr Nurse; 2007; 40(3):28. PubMed ID: 17915614
    [No Abstract]   [Full Text] [Related]  

  • 28. Over-the-counter sales of statins and other drugs for asymptomatic conditions.
    Tinetti ME
    N Engl J Med; 2008 Jun; 358(25):2728-32. PubMed ID: 18565867
    [No Abstract]   [Full Text] [Related]  

  • 29. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence-based guidelines for cardiovascular risk reduction: the safety and efficacy of high-dose statin therapy.
    Ashen MD; Foody JM
    J Cardiovasc Nurs; 2009; 24(6):429-38. PubMed ID: 19786883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution.
    Gumbs PD; Verschuren WM; Souverein PC; Mantel-Teeuwisse AK; de Wit GA; de Boer A; Klungel OH
    Br J Clin Pharmacol; 2007 Nov; 64(5):680-5. PubMed ID: 17875197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Statins with a perspective of lifelong therapy].
    Ertaş FS
    Turk Kardiyol Dern Ars; 2009 Mar; 37 Suppl 2():29-36. PubMed ID: 19404048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Statin and ezetimibe combination therapy in cardiovascular disease.
    Dembowski E; Davidson MH
    Curr Opin Endocrinol Diabetes Obes; 2009 Apr; 16(2):183-8. PubMed ID: 19262375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Compliance after switching from branded to generic statins.
    Romanelli RJ; Jukes T; Segal JB
    Pharmacoepidemiol Drug Saf; 2014 Oct; 23(10):1093-100. PubMed ID: 24817435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy, safety, and pharmaco-economical aspects of the therapy for dyslipidemia with brand-name and generic statins].
    Ol'binskaia LI; Danilogorskaia IuA
    Ter Arkh; 2003; 75(12):47-50. PubMed ID: 14959470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching statins.
    Moon JC; Bogle RG
    BMJ; 2006 Jun; 332(7554):1344-5. PubMed ID: 16763226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Which is the best statin for the postoperative coronary artery bypass graft patient?
    Conway AM; Musleh G
    Eur J Cardiothorac Surg; 2009 Oct; 36(4):628-32. PubMed ID: 19524449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
    Stewart RA
    Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
    Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
    Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding practice patterns and low-density lipoprotein cholesterol goal attainment implications of switching patients from simvastatin in a health plan setting.
    Harley CR; Gandhi SK; Anoka N; Bullano MF; McKenney JM
    Am J Manag Care; 2007 Dec; 13 Suppl 10():S276-81. PubMed ID: 18095778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.